Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC)

Soft Tissue Sarcoma Clinical Trial

Official title:

ADI-PEG 20 or Placebo Plus Gemcitabine and Docetaxel in Previously Treated Subjects With Leiomyosarcoma (ARGSARC): A Randomized, Double Blind, Multi-Center Phase 3 Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05712694
• Other study ID #: POLARIS2022-001
• Status: Recruiting
• Phase: Phase 3
• Start date: November 29, 2023
• Est. completion date: December 30, 2027

Study information

• Verified date: December 2023
• Source: Polaris Group
• Contact: Mirla Langlois
• Phone: 858-452-6688
• Email: mlanglois[@]polarispharma.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To compare the efficacy and safety in subjects with advanced or metastatic LMS previously treated with an anthracycline.

Description:

This is a global, multicenter, randomized, double-blind, placebo-controlled, parallel-group phase 3 trial that will compare the efficacy and safety in subjects with advanced or metastatic LMS previously treated with an anthracycline.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 300
• Est. completion date: December 30, 2027
• Est. primary completion date: December 30, 2027
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 99 Years

Eligibility

Inclusion Criteria:

• A subject will be eligible for study participation if he/she meets the following criteria:

1. Histologically or cytologically confirmed, grade 2 or 3, LMS STS that would be standardly treated with Gem or GemDoc.

2. Determination of LMS subtype: uterine or non-uterine.

3. Measurable disease per RECIST 1.1 (Appendix A), defined as lesions that can be accurately measured in at least one dimension (longest diameter to be recorded) as = 10 mm with CT scan, as = 20 mm by chest x-ray, or = 10 mm with calipers by clinical exam.

4. Previous treatment with up to 2 systemic regimens, including at least 1 systemic regimen containing doxorubicin.

5. Treatment > one year ago in the adjuvant/neoadjuvant setting with Gem or Doc is allowed.

6. Age >18 years.

7. Eastern Cooperative Oncology Group (ECOG) performance status of < 1 at enrollment (Appendix B).

8. Leukocytes = 3,000/mcL.

9. Absolute neutrophil count = 1,500/mcL.

10. Platelets = 100,000/mcL.

11. Total bilirubin = 2 x ULN. (= 3 x ULN for potential subjects with Gilbert's Disease)

12. AST(SGOT)/ALT(SGPT) = 3 x ULN (or = 5 x ULN if liver metastases are present)

13. Creatinine clearance = 60 mL/min (by Cockcroft-Gault equation).

14. Serum uric acid = 8 mg/dL (with or without medication control).

15. QTc interval range from 350 to 450 ms for adult men and from 360 to 460 ms for adult women.

16. Subjects and their partners must be asked to use appropriate contraception. They must agree to use 2 forms of contraception or agree to refrain from intercourse for the duration of the study and for 35 days after the last dose of ADI-PEG 20 or for at least 3 months (male subjects) or 6 months (female subjects) after treatment with gemcitabine, whichever is the longer duration.

17. Ability to understand and willingness to sign the informed consent form.

18. No concurrent investigational drug studies are allowed.

Exclusion Criteria:

• A subject will not be eligible for study participation if he/she meets any of the exclusion criteria:

1. Subjects with history of another primary cancer, including co-existent second malignancy, with the exception of: a) curatively resected non-melanoma skin cancer; b) curatively treated cervical carcinoma in situ; or c) other primary solid tumor with no known active disease present in the opinion of the Investigator will not affect subject outcome in the setting of current diagnosis.

2. Currently receiving other investigational agents.

3. Prior treatment with ADI-PEG 20, Gem or Doc. Patients treated > one year ago in the adjuvant/neoadjuvant setting with Gem or Doc are allowed to be enrolled.

4. Known brain metastases. Such patients must be excluded from this trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events.

5. History of allergic reactions attributed to compounds of similar chemical or biologic composition to ADI-PEG 20, Gem, Doc, polysorbate 80, pegylated compounds, or other agents used in this study.

6. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.

7. History of seizure disorder not related to underlying cancer.

8. Grade 2 or higher neuropathy.

9. Pregnant and/or breastfeeding. Women of childbearing potential must have a negative pregnancy test within 14 days of study entry.

10. Known HIV-positivity on combination antiretroviral therapy because of the potential for pharmacokinetic interactions with the study treatment. In addition, these patients are at increased risk of lethal infections when treated with marrow-suppressive therapy. Appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated.

Related Conditions & MeSH terms

• Leiomyosarcoma
• Sarcoma
• Soft Tissue Sarcoma

Intervention

Drug:
• ADI PEG20
Treatment for advanced or metastatic uterine/non-uterine leiomyosarcoma (LMS)

Other:
• Placebo
Treatment for advanced or metastatic uterine/non-uterine leiomyosarcoma (LMS)

Locations

Country	Name	City	State
Canada	McGill University Health Centre (Quebec)	Montréal	Quebec
Canada	UHN - Princess Margaret Cancer Center (Ontario)	Toronto	Ontario
Taiwan	National Taiwan University Hospital	Taipei
Taiwan	Taipei Veterans General Hospital	Taipei
United States	University of Michigan	Ann Arbor	Michigan
United States	University of Colorado Cancer Center/ CU Anschutz Medical Campus	Aurora	Colorado
United States	Northwestern	Chicago	Illinois
United States	University Hospitals Cleveland Medical Center	Cleveland	Ohio
United States	Ohio State University Wexner Medical Center/ The James Cancer Hospital and Solove Research Institute	Columbus	Ohio
United States	Duke Cancer Institute	Durham	North Carolina
United States	Indiana University	Indianapolis	Indiana
United States	University of Iowa	Iowa City	Iowa
United States	University of Miami/ Sylvester Comprehensive Cancer Center	Miami	Florida
United States	UPenn (Abramson Cancer Center, Pennsylvania Hospital)	Philadelphia	Pennsylvania
United States	Washington University School of Medicine - Siteman Cancer Center	Saint Louis	Missouri
United States	Wake Forest Baptist (Atrium Health)	Salem	North Carolina
United States	Moffitt Cancer Center	Tampa	Florida

Sponsors (1)

Lead Sponsor	Collaborator
Polaris Group

Countries where clinical trial is conducted

United States,  Canada,  Taiwan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Primary End Point of PFS	The primary objective is to compare the primary endpoint of PFS in subjects treated with the arginine degrading enzyme ADI-PEG 20 plus Gem and Doc (ADIGemDoc) or PBO plus Gem and Doc (PBOGemDoc) in the 2nd or 3rd line setting using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 assessed by blinded independent central review committee (BICR)	Subjects will receive triplet combination treatment followed by weekly monotherapy ADI-PEG 20 or PBO (Each cycle is 21 days). Subjects tolerating chemotherapy may continue chemotherapy beyond 8 cycles and up to 104 weeks (~2 years).
Secondary	Secondary End Point of ORR (CR+PR)	The secondary objectives are to compare ADIGemDoc versus PBOGemDoc with respect to: Objective response rate (ORR) (complete response [CR] + partial response [PR]) The secondary endpoint of ORR will be assessed by BICR using RECIST 1.1 and tested using a CMH test stratified by the stratification factors used during the randomization based on the ITT population.	Subjects will receive triplet combination treatment followed by weekly monotherapy ADI-PEG 20 or PBO (Each cycle is 21 days). Subjects tolerating chemotherapy may continue chemotherapy beyond 8 cycles and up to 104 weeks (~2 years).
Secondary	Secondary End Point of Overall Survival (OS)	The secondary objectives are to compare ADIGemDoc versus PBOGemDoc with respect to: OS; The secondary endpoint of OS will be tested using a log-rank test stratified by the stratification factors used during the randomization based on the ITT population. A stratified Cox model will be used to estimate HR and 95% CI, and KM curves will be used to estimate OS median and 95% CI.	Subjects will receive triplet combination treatment followed by weekly monotherapy ADI-PEG 20 or PBO (Each cycle is 21 days). Subjects tolerating chemotherapy may continue chemotherapy beyond 8 cycles and up to 104 weeks (~2 years).
Secondary	Secondary End Point of Safety and Tolerability	All clinically significant abnormalities and deteriorations will be followed and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Event (NCI CTCAE V5).	Subjects will receive triplet combination treatment followed by weekly monotherapy ADI-PEG 20 or PBO (Each cycle is 21 days). Subjects tolerating chemotherapy may continue chemotherapy beyond 8 cycles and up to 104 weeks (~2 years).